First, marked intratumoral heterogeneity for HER2 amplification has been well documented and is thought to represent subclonal diversity within tumor samples [49], so analysis of 1–5 CTCs might not be sufficient to detect HER2+ CTCs in a heterogeneous sample. Here, ERBB2 is linked to neoplasm.